Glucose Baxter (Glucose Monohydrate)

Glucose Baxter is an intravenous solution containing glucose monohydrate, supplied at a standard concentration (strength not specified) for parenteral use. Distributed in the European Union, it is classified as an excipient/solvent and listed under ATC code A12AA01 as a nutritional supplement. The product delivers an immediate source of glucose for cellular metabolism when administered intravenously and is stored under controlled conditions to ensure stability through proper handling.

Glucose Baxter is indicated for several clinical situations where rapid glucose delivery or fluid support is required.

- Treatment of acute hypoglycemia to quickly raise blood glucose levels. - Fluid and electrolyte replacement in patients unable to tolerate oral intake. - Caloric support as part of parenteral nutrition regimens. - Dilution and carrier solution for compatible intravenous medications. - Intraoperative glucose supplementation during surgical procedures. - Maintenance of blood glucose homeostasis during critical care monitoring. - Provision of isotonic solution to assist with volume resuscitation when combined with electrolytes.

Adverse reactions to Glucose Baxter are generally related to the intravenous administration of a glucose solution and may vary in frequency. These events are typically dose‑related and resolve after discontinuation or appropriate management.

Common: - Mild hyperglycemia with transient elevation of blood glucose. - Local irritation or pain at the infusion site. - Nausea or vomiting if administered rapidly. - Electrolyte shifts such as mild hyponatremia. - Transient headache associated with rapid infusion rates. - Mild metabolic acidosis in patients with impaired renal function.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Allergic reactions including rash, urticaria, or anaphylaxis. - Fluid overload causing pulmonary edema in susceptible patients.

When using Glucose Baxter, clinicians should observe specific precautions to minimize risks and ensure safe administration.

- Verify patient’s blood glucose level before infusion to avoid overtreatment. - Adjust infusion rate in patients with cardiac or renal insufficiency. - Monitor fluid balance and signs of overload, especially in critically ill patients. - Use aseptic technique to prevent contamination of the intravenous solution. - Check compatibility with other IV drugs; avoid mixing with solutions containing calcium or phosphate. - Document any adverse reactions promptly in the patient’s medical record.

Glucose Baxter may interact with certain intravenous agents or conditions; awareness of these interactions helps prevent complications.

Avoid: - Co‑administration with high‑dose insulin infusions without glucose monitoring. - Mixing with calcium‑containing solutions that can precipitate calcium gluconate. - Concurrent use with hyperosmolar agents that increase risk of fluid overload. - Avoid rapid bolus administration in patients with compromised blood‑brain barrier.

Use with caution: - Concurrent administration of diuretics; monitor electrolyte balance closely. - Use in patients receiving total parenteral nutrition; adjust carbohydrate calculations. - Administration alongside beta‑adrenergic agonists; observe for exaggerated hyperglycemic response.